RxDoctor Payments Data

Steve Flanagan, MD

Physical Medicine and Rehabilitation · New York, NYNPI 1962470815

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (53.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Avanir Pharmaceuticals, Inc. accounts for 77.3% of it on its own, with 2 other manufacturers making up the rest.

$2,015in general payments, 2019–2025

Across 24 payments — averaging $83.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$2K
  • Merz North America, Inc.$422
  • Medtronic$35
$34,140in research payments, 2019–2025

Across 7 payments — averaging $4877.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Avanir Pharmaceuticals, Inc.$22K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$13K

What the payments were for

  • Travel & lodging$1,07253%
  • Food & beverage$48724%
  • Education$45623%

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Avanir Pharmaceuticals, Inc.16$1,558
Merz North America, Inc.6$422
Medtronic(2 entities)2$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,015 in reported general payments places this provider in the 85th percentile of 872 physical medicine and rehabilitation providers in New York.

See all physical medicine and rehabilitation providers in New York

Medicare billing

Part B allowed, 2024
$38,653
Medicare patients
169
Services billed
467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Methylphenidate ErMethylphenidate Hcl20$1,359
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine28$552
Chlorpromazine Hcl12$399
Zolpidem Tartrate ErZolpidem Tartrate12$316
Venlafaxine Hcl ErVenlafaxine Hcl17$316
Buspirone Hcl12$181
Methylphenidate Hcl22$172

Paid to pharmacies, not to this prescriber.

Other physical medicine and rehabilitation in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →